Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate

All-Stock Deal Merges Two San Diego Firms

Deal Snapshot: Equillium will gain $33m, extending its cash runway into 2024 and past several upcoming milestones, but it will seek a strategic partner for Metacrine’s stalled FXR agonist MET642.

Isometric arrow formed by two merging black and white lines on turquoise blue — Equillium will use Metacrine's cash for its own programs • Source: Shutterstock

Who:Equillium, Inc./Metacrine, Inc.

What: Equillium will acquire Metacrine in an all-stock transaction, but it will seek a strategic partner to develop the target...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate

All-Stock Deal Merges Two San Diego Firms

Read the full article – start your free trial today!

More from Deals

More from Business